Acrivon Therapeutics, Inc.: Promising Advancements and Strong Buy Rating Backed by Innovative Pipeline and Solid Financial Position
TD Cowen analyst Marc Frahm has maintained their bullish stance on ACRV stock, giving a Buy rating today. Marc Frahm has given his Buy rating ...
Springworks Therapeutics: Strong Cash Position and Promising Drug Approval Outlook Justify Buy Rating
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Springworks Therapeutics (SWTX – Research ...